AI’s role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy

Abstract

This paper examines the transformative impact of artificial intelligence (AI) on pharmacogenomics, signaling a paradigm shift in personalized medicine. With a focus on enhancing drug response prediction and treatment optimization, AI, particularly machine learning and deep learning algorithms, navigates the complexity of genomic data. By elucidating intricate relationships between genetic factors and drug responses, AI augments the identification of genetic markers and contributes to the development of comprehensive models. The review emphasizes AI’s role in guiding treatment decisions, minimizing adverse reactions, and optimizing drug dosages in clinical settings. Ethical considerations, challenges, and future directions are also discussed. This work underscores the synergy of AI and pharmacogenomics, offering a more effective and patient-centric approach to drug therapy, marking a significant advancement in the field of personalized medicine.

Keywords

Artificial intelligence (AI) / Pharmacogenomics / Personalized-medicine

References

[1] Rykov MY. [The evolution of personalized medicine: publications review]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2022;30(6):1211–1219.

[2] Visvikis-Siest S, et al. Milestones in personalized medicine: from the ancient time to nowadays—the provocation of COVID-19. Front Genet. 2020;11:569175.

[3] Bezdieniezhnykh N, Reznikova V, Rossylna O. Scientific-practical and legal problems of implementation of the personalized medicine. Exp Oncol. 2017.

[4] Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020:369–394.

[5] Naik K, et al. Current status and future directions: the application of artificial intelligence/machine learning (AI/ML) for precision medicine. Clin Pharmacol Therapeut. 2023.

[6] Schleidgen S, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14(1):1–12.

[7] Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109(6):952–963.

[8] Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. Obstet Gynecol Surv. 2015;70(10):612–614.

[9] T PA, et al. Pharmacogenomics: the right drug to the right person. J Clin Med Res. 2009;1(4):191–194.

[10] Omer MS. Literature review concerning the challenges of implementing pharmacogenetics in primary care practice. Cureus. 2020;12(8):e9616.

[11] Nicholson WT, et al. Considerations when applying pharmacogenomics to your practice. Mayo Clin Proc. 2021;96(1):218–230.

[12] Ahmed I, et al. A review of literature on the pharmacogenomics of single-nucleotide polymorphisms. Biomedical and Biotechnology Research Journal (BBRJ). 2022;6(1).

[13] Ghim J-L, Ahn S. Transforming clinical trials: the emerging roles of large language models. Translational and Clinical Pharmacology. 2023;31(3):131.

[14] Tremmel R, et al. Circulating biomarkers instead of genotyping to establish metabolizer phenotypes. Annu Rev Pharmacol Toxicol. 2024;64(1):65–87.

[15] Nageeta F, et al. Precision medicine approaches to diabetic kidney disease: personalized interventions on the horizon. Cureus. 2023;15(9).

[16] Ryan DK, et al. Artificial intelligence and machine learning for clinical pharmacology. Br J Clin Pharmacol. 2024;90(3):629–639.

[17] Evans W, et al. Precision medicine—are we there yet? A narrative review of precision medicine’s applicability in primary care. J Personalized Med. 2024;14(4):418.

[18] Szalai C. Arguments for and against the whole-genome sequencing of newborns. Am J Tourism Res. 2023;15(10):6255.

[19] Zahra MA, et al. The synergy of artificial intelligence and personalized medicine for the enhanced diagnosis, treatment, and prevention of disease. Drug Metabolism and Personalized Therapy. 2024.

[20] Marchiò C, et al. Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer. Pathologica. 2023;115(6):292.

[21] Yang Q, et al. Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy. Cells. 2024;13(13):1106.

[22] Quinn TP, et al. A primer on the use of machine learning to distil knowledge from data in biological psychiatry. Mol Psychiatr. 2024;29(2):387–401.

[23] Tremmel R, et al. Translating pharmacogenomic sequencing data into drug response predictions—how to interpret variants of unknown significance. Br J Clin Pharmacol. 2023.

[24] Zeng S, et al. Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors. Front Med. 2024;11:1365524.

[25] Kiguba R, et al. Navigating duplication in pharmacovigilance databases: a scoping review. BMJ Open. 2024;14(4):e081990.

[26] Zhou Y, et al. Review of personalized medicine and pharmacogenomics of anti-cancer compounds and natural products. Genes. 2024;15(4):468.

[27] Singh S, et al. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. Biochem Biophys Res Commun. 2023.

[28] Paliwal A, et al. Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine. Expet Opin Drug Metabol Toxicol. 2024;20(4):181–195.

[29] Mohamad T, et al. Individualizing medicinal therapy post heart stent implantation: tailoring for patient factors. Cureus. 2023;15(8).

[30] Abdelhalim H, et al. Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. Front Genet. 2022;13:929736.

[31] Johnson KB, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci. 2021;14(1):86–93.

[32] Dias R, Torkamani A. Artificial intelligence in clinical and genomic diagnostics. Genome Med. 2019;11(1):70.

[33] Silva P, et al. Implementation of pharmacogenomics and artificial intelligence tools for chronic disease management in primary care setting. J Personalized Med. 2021;11(6).

[34] Manzini A, Lee T. Current and emerging capabilities of AI-powered genomics, and associated ethical. Legal and Political Debates. 2023.

[35] van der Lee M, et al. Technologies for pharmacogenomics: a review. Genes. 2020;11(12):1456.

[36] Kidwai-Khan F, et al. Pharmacogenomics driven decision support prototype with machine learning: a framework for improving patient care. Frontiers in big Data. 2022;5:1059088.

[37] Kalinin AA, et al. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics. 2018;19(7):629–650.

[38] Iyer RK, et al. Artificial intelligence and pharmacogenomics: a timely synergy for individualizing medicine. Advances in Molecular Pathology. 2019;2(1):111–118.

[39] Lin E, Lin C-H, Lane H-Y. Machine learning and deep learning for the pharmacogenomics of antidepressant treatments. Clinical Psychopharmacology and Neuroscience. 2021;19(4):557.

[40] Primorac D, et al. Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics. 2020;21(2):141–156.

[41] Hassan M, et al. Innovations in genomics and big data analytics for personalized medicine and health care: a review. Int J Mol Sci. 2022;23(9):4645.

[42] Wei JC-C, Chang W-C, Mushiroda T. Big Data, Pharmacogenomics and Real-World Research in Pharmacology. Frontiers Media SA;2020:1239.

[43] Wei WQ, et al. Machine learning challenges in pharmacogenomic research. Clin Pharmacol Ther. 2021;110(3):552–554.

[44] James E, Rabbi F. Fortifying the IoT landscape: strategies to counter security risks in connected systems. Tensorgate Journal of Sustainable Technology and Infrastructure for Developing Countries. 2023;6(1):32–46.

[45] Jhawat V, et al. Artificial intelligence and data science in pharmacogenomics-based drug discovery: future of medicines. In: Data Science for Genomics. Elsevier;2023:85–97.

[46] van der Lee M, Swen JJ. Artificial intelligence in pharmacology research and practice. Clinical and Translational Science. 2023;16(1):31–36.

[47] Kuenzi BM, et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell. 2020;38(5):672–684. e6.

[48] Adam G, et al. Machine learning approaches to drug response prediction: challenges and recent progress. npj Precis Oncol. 2020;4(1):19.

[49] Partin A, et al. Deep learning methods for drug response prediction in cancer: predominant and emerging trends. Front Med. 2023;10:1086097.

[50] Park A, Lee Y, Nam S. A performance evaluation of drug response prediction models for individual drugs. Sci Rep. 2023;13(1):11911.

[51] O’Shea J, et al. Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. Pharmacogenomics J. 2022;22(2):89–99.

[52] Routhier E, Mozziconacci J. Genomics enters the deep learning era. PeerJ. 2022;10:e13613.

[53] Shen X, et al. A brief review on deep learning applications in genomic studies. Frontiers in Systems Biology. 2022;2:877717.

[54] Eraslan G, et al. Deep learning: new computational modelling techniques for genomics. Nat Rev Genet. 2019;20(7):389–403.

[55] Koumakis L. Deep learning models in genomics;are we there yet? Comput Struct Biotechnol J. 2020;18:1466–1473.

[56] Han K, et al. A review of approaches for predicting drug-drug interactions based on machine learning. Front Pharmacol. 2022;12:814858.

[57] Bhatnagar R, et al. How can natural language processing help model informed drug development?: a review. JAMIA open. 2022;5(2):ooac043.

[58] Wu H-Y, Chiang C-W, Li L. Text mining for drug–drug interaction. Biomedical literature mining. 2014:47–75.

[59] Kumar M, et al. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacol Rep. 2023;75(1):3–18.

[60] Chang W-C, et al. Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu Rev Pharmacol Toxicol. 2021;61:65–84.

[61] Chin MH, et al. Guiding principles to address the impact of algorithm bias on racial and ethnic disparities in health and health care. JAMA Netw Open. 2023;6(12):e2345050.

[62] Fritzsche M-C, et al. Ethical layering in AI-driven polygenic risk scores—new complexities, new challenges. Front Genet. 2023;14:1098439.

[63] Chen RJ, et al. Algorithmic fairness in artificial intelligence for medicine and healthcare. Nat Biomed Eng. 2023;7(6):719–742.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.